Dr. Rynn is Chair for the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. She is an internationally-renowned expert in the treatment of pediatric mood and anxiety disorders. She has spent her career focused on improving treatments for children, adolescents, and young adults with treatment refractory mood and anxiety disorders. Her most recent studies have examined novel augmentation treatment strategies for pediatric Obsessive-Compulsive Disorder and treatment models for adolescent depression in the primary care setting. Dr. Rynn received her medical degree from Rutgers University. She completed her internship and residency in psychiatry at the University of Pennsylvania Perelman School of Medicine and served as Chief Resident. After completing her adult psychiatry training, she completed a Child and Adolescent Psychiatry Fellowship at the Children’s Hospital of Philadelphia followed by a Neuropsychopharmacology Research Fellowship sponsored by the NIMH at the University of Pennsylvania Perelman School of Medicine. Prior to joining Columbia University, Dr. Rynn was medical director of the Mood and Anxiety Disorders Section of the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine.
The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination.
Primary Care: Meeting the Mental Health Care Needs of Adolescents With Depression.
Secondary Outcomes From the Child/Adolescent Anxiety Multimodal Study: Implications for Clinical Practice.
Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study.
Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
Child/adolescent anxiety multimodal study: Evaluating safety
Read Full TextEfficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis.
Web-based interventions for youth internalizing problems: a systematic review.
Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.
Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
SMARTer discontinuation trial designs for developing an adaptive treatment strategy.
Psychopharmacologic treatment of children and adolescents with anxiety disorders.
Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder.
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders
Read Full TextDr Barber and colleagues reply
Read Full TextShort-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial.
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.
Screening parents during child evaluations: exploring parent and child psychopathology in the same clinic.
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.
Childhood anxiety disorders: Best treatment options and practice
Read Full TextCognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
Influence of gender on the clinical presentation of generalized anxiety disorder, and response to treatment with Pregabalin
Read Full TextThe varied manifestations of anxiety disorder
Read Full TextEfficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials
Read Full TextSocial anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment.
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
The psychometric properties of the MASC in a pediatric psychiatric sample.
Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.
49th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. 22-27 October 2002, San Francisco, CA, USA.
Ziprasidone-associated mania: a case series and review of the mechanism.
Efficacy and safety of nefazadone in the treatment of adolescents with major depressive disorder
Read Full TextPlacebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.
Assessment of Psychiatric Comorbidity in Children Infected with Human Immunodeficiency Virus, Type 1
Read Full TextTreating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications.
